Compare Msci Inc (MSCI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Natera Inc. Common Stock — how do they compare? Msci Inc trades at $560.52 (market cap $41.29B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Msci Inc pays a 1.44% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 83 Days and Natera Inc. Common Stock for 0 Days on average.
| MSCI | NTRA | |
|---|---|---|
Market Cap | $41.29B | $57.03B |
Volume | 468,436 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $643.83 | $425.64 |
52-Week Low | $511.84 | $179.42 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $47.46B | $56.18B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $560.52, down 1.32% today, with strong profitability (40.73% net margin) and consistent revenue growth from $2.2B in 2022 to $3.1B in 2025. Recent Q2 2026 earnings missed expectations at $4.94 EPS, but Q1 and Q4 2025 beat. Technicals show a bullish moving average signal with RSI at 59.48 neutral, while analyst consensus is strongly bullish with a $701.71 price target. The company maintains robust cash flow from operations of $1.6B in 2025.
Outlook remains positive driven by recurring revenue streams and market position, though high valuation (P/E 31.06) and debt levels ($4.51B long-term) pose risks. The upcoming Q3 2026 earnings on October 20, 2026, is a key catalyst. Investors should weigh strong fundamentals against premium pricing and macroeconomic sensitivity.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
